Clinical Trial Update: Study to Assess Safety, Tolerability and Efficacy of Incremental Doses of MGB-BP-3 in Patients With CDAD [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating incremental doses of MGB-BP-3 for safety, tolerability, and efficacy in Clostridium difficile infection has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridium Difficile Infection

Drugs mentioned

• MGB-BP-3

Snippet

Sponsor: MGB Biopharma Limited | Conditions: Clostridium Difficile Infection | Phase 2 | Status: COMPLETED